drugset / Trial / NCT06685887
A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
Phase 2
Recruiting
34 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
BeiGene · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-center, prospective, phase II clinical trial aimed at assessing the impact of HIPEC combined with systemic chemotherapy and immune checkpoint inhibitors on the R0 resection rate in patients with peritoneal metastasis from gastric cancer. Furthermore, it seeks to analyze the effects of this treatment strategy on overall survival (OS), progression-free survival (PFS), PCI and adverse reaction rates.
Timeline
- Start
- 2025-02-15
- Primary completion
- 2027-07
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 130 mg | Intravenous |
| Subject | S-1 | Small molecule | 40 mg | — |
| Subject | S-1 | Small molecule | 60 mg | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |